PD Hinduja Hospital in Khar has made a groundbreaking move by launching CAR-T cell therapy with ImmunoACT, introducing NexCAR19 (Actalycabtagene autoleucel) as India's first gene-modified cell treatment.

This therapy is targeted at patients aged 15 and above facing relapsed or refractory B-cell lymphoma and B-acute lymphoblastic leukemia.

Developed by ImmunoACT in collaboration with IIT-Bombay and Tata Memorial Centre, NexCAR19 transforms T-cells into potent cancer fighters. This autologous CAR-T cell therapy specifically targets the CD19 protein, offering significant benefits to patients unresponsive to traditional treatments.

One of the key advantages of CAR-T therapy is its ability to provide a comprehensive treatment with a single infusion, thereby enhancing the quality of life for patients. Remarkably, this treatment is offered at one-tenth of the global cost, making it a promising solution for patients in need.

Gautam Khanna, CEO of PD Hinduja Hospital, expressed pride in being among the first healthcare institutions in Mumbai to provide CAR-T cell therapy. Dr (Prof) Vijay Patil, Consultant in Medical Oncology at PD Hinduja Hospital, sees CAR-T therapy as a beacon of hope for patients dealing with resistant cancers. Dr Ashay Karpe, Consultant in Hemato-Oncology, anticipates the program to bring new hope to cancer patients.

Shirish Arya, Co-founder & Director of Business Development and Corporate Strategy at ImmunoAct, highlighted the positive impact of the collaboration with PD Hinduja Hospital. The partnership aims to enhance accessibility to NexCAR19, contributing to improved treatment outcomes and enhancing the overall quality of life for patients.